All In Biotech

Drug Trial Radar · NCT07027527

An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis

A Phase 1b, Open-label, Randomized, Multicenter, Active Comparator Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Combination of APG777 + APG990 in Adults With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

86

Actual

Start

Jun 4, 2025

Primary completion

Aug 29, 2026

Study completion Dec 2027

Sponsor

Lead sponsor
Apogee Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) parameters of the combination of APG777 + APG990 in adults with moderate-to-severe atopic dermatitis (AD), in comparison to dupilumab. The duration of the study will be approximately 82 weeks for each participant and will consist of a Screening Period (up to 6 weeks), Treatment Period (Baseline-Week 24), and Follow-up Period (Week 28-Week 76).

Conditions

  • Atopic Dermatitis

Interventions

  • APG777Drug

    Subcutaneous (SC) injection

  • APG990Drug

    SC injection

  • DupilumabDrug

    SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 24 weeks

Locations

20 sites in 3 countries. Site status is shown where the registry gives one.

  • Investigational Site

    Darlinghurst, New South Wales, Australia

  • Investigational Site

    Kogarah, New South Wales, Australia

  • Investigational Site

    Westmead, New South Wales, Australia

  • Investigational Site

    Woolloongabba, Queensland, Australia

  • Investigational Site

    Carlton, Victoria, Australia

  • Investigational Site

    East Melbourne, Victoria, Australia

  • Investigational Site

    Mitcham, Victoria, Australia

  • Investigational Site

    Parkville, Victoria, Australia

  • Investigational Site

    Fremantle, Western Australia, Australia

  • Investigational Site

    London, Ontario, Canada

  • Investigational Site

    Peterborough, Ontario, Canada

  • Investigational Site

    Richmond Hill, Ontario, Canada

  • Investigational Site

    Toronto, Ontario, Canada

  • Investigational Site

    Toronto, Ontario, Canada

  • Investigational Site

    Toronto, Ontario, Canada

  • Investigational Site

    Montreal, Quebec, Canada

  • Investigational Site

    Québec, Quebec, Canada

  • Investigational Site

    Sherbrooke, Quebec, Canada

  • Investigational Site

    Auckland, New Zealand

  • Investigational Site

    Hamilton, Waitako, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.